Pancreatic Cancer
If it’s your first time on this website, please read the disclaimer section.
Jul 13 – Jul 20, 2026
Adjuvant Chemotherapy ± Chemoradiotherapy for Adenocarcinoma of the Pancreatic Head: Results of the Radiotherapy Random Assignment of NRG Oncology/RTOG 0848.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This multicenter, randomized phase III trial (NRG Oncology/RTOG 0848, Step 2) investigated whether adding fluoropyrimidine sensitized radiotherapy (CXRT) to adjuvant chemotherapy improves overall survival (OS) after curative resection for pancreatic head adenocarcinoma. Overall, adjuvant CXRT did not significantly improve OS (HR 0.96 [90% CI, 0.79 to 1.18], p=.77) or DFS, but increased grade 3 toxicity (38% vs 19%, p<.001). Significantly, CXRT improved OS (p=.0063) and DFS (p=.014) in node-negative patients. These findings suggest a potential benefit of adjuvant CXRT for node-negative pancreatic cancer patients, warranting further investigation with current systemic therapies.
10.1200/JCO-25-02520
Jun 29 – Jul 06, 2026
Robotic versus Open Pancreatoduodenectomy (PORTAL): multicentre, single masked, phase 3, non-inferiority randomised controlled trial.
BMJ-BRIT MED J · Q1 JOURNAL - RANK #5/332TOP-TIER
This phase 3 non-inferiority RCT compared robotic (RPD) versus open pancreatoduodenectomy (OPD) in 268 adults with resectable pancreatic or periampullary disease across seven Chinese high-volume centers. The primary outcome, time to postoperative functional recovery, was significantly shorter with RPD (restricted mean event time 12.1 vs 16.0 days; difference -3.9 days, P<0.001). RPD also showed lower overall morbidity (31.1% vs 36.1%) and fewer Clavien-Dindo ≥II complications (23.5% vs 34.4%), though operative time and total costs were higher. For clinicians focused on cancer, the study directly addresses surgical management of resectable pancreatic cancer, demonstrating non-inferior oncological safety with faster recovery in specialized centers.
10.1136/bmj-2026-319692
Jun 01 – Jun 08, 2026
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.
NEW ENGL J MED · Q1 JOURNAL - RANK #2/332TOP-TIER
This phase 3, international, open-label, randomized trial investigated daraxonrasib versus chemotherapy in 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). Daraxonrasib, an oral RAS(ON) inhibitor, significantly improved median overall survival to 13.2 months compared to 6.6 months with chemotherapy in the KRAS G12 population (HR 0.40, P<0.001). Similarly, median progression-free survival was 7.3 months versus 3.5 months (HR 0.45, P<0.001). These findings demonstrate daraxonrasib’s superior efficacy, offering a promising new therapeutic option for clinicians managing advanced pancreatic cancer.
10.1056/NEJMoa2605555
May 25 – Jun 01, 2026
Longitudinal Risk for Suicidal Self-Directed Violence Among Veterans With Cancer.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This national cohort study assessed longitudinal risks and methods for suicidal self-directed violence (SSDV) among 292,271 veterans with invasive solid or hematologic cancer (2014-2023) using registries. Overall, 2400 SSDV events occurred (203 per 100,000 person-years), with poisoning most common (26%). High rates were found in patients with CNS, pancreas, head and neck, liver and biliary system, and thyroid cancers, advanced cancer (261 per 100,000 person-years), severe frailty, chronic mental illness, and high pain scores. Risks persisted five years post-diagnosis for younger (≤45 years), unmarried, advanced cancer, and CNS cancer patients, highlighting vulnerable subgroups. This emphasizes the critical need for systematic tracking of suicidal behaviors and tailored screening strategies within comprehensive cancer care, especially for these high-risk populations.
10.1001/jamaoncol.2026.1459
May 11 – May 18, 2026
Age-Dependent Interplay of Modifiable Risk Factors and Genetic Risk in Pancreatic Cancer.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This prospective cohort study investigated the age-dependent interplay of modifiable and genetic risk factors for pancreatic cancer (PC) in 290,645 UK Biobank participants over 11.7 years. It found that while polygenic risk (PRS) consistently increased PC risk across all ages, modifiable risk (MRS) showed stronger associations in younger adults (<60 years, HR 1.69; 95% CI, 1.43-2.01). The absolute difference in 10-year cumulative incidence between high and low MRS was most pronounced among high PRS individuals, particularly in younger age groups (6.1-fold greater). These findings highlight the critical importance of initiating early-life prevention strategies, especially targeting modifiable risk factors in younger adults with high genetic predisposition to PC.
10.1001/jamaoncol.2026.1192
May 04 – May 11, 2026
Pancreatic cancer.
NAT REV DIS PRIMERS · Q1 JOURNAL - RANK #3/332TOP-TIER
This abstract reviews pancreatic ductal adenocarcinoma, a deadly malignancy, focusing on advances in diagnosis, treatment, and future directions. It highlights improved outcomes with multiagent chemotherapy and surgical innovations, which have enhanced complete resection rates and converted unresectable disease. Emerging strategies include precision medicine, personalized RNA vaccines, KRAS-directed agents, and AI-assisted early detection. The review is highly relevant to cancer research, emphasizing multidisciplinary, biology-guided approaches to transform pancreatic cancer into a more manageable condition.
10.1038/s41572-026-00699-6